Table 1 Baseline characteristics of the participants by allocated group and total. Data are presented as numbers (N) unless otherwise stated
Characteristic | Intervention group (N = 10) | Control group (N = 10) | Total |
|---|---|---|---|
Women | 6 | 6 | 12 (60 %) |
Age (years); M(SD) | 64.5 (8.5) | 54.0 (14.0) | 59.3 (12.5) |
Cohabiting | 2 | 6 | 8 (42 %) |
Highest attained education | |||
Primary school | 5 | 2 | 7 (35 %) |
High school | 0 | 3 | 3 (15 %) |
Short to middle higher education | 4 | 5 | 9 (45 %) |
Long higher education (university) | 1 | 0 | 1 (5 %) |
Occupation | |||
Unemployed | 1 | 0 | 1 (5 %) |
Employed full time | 1 | 1 | 2 (10 %) |
Employed part time | 1 | 1 | 2 (10 %) |
Disease-related retirement | 1 | 3 | 4 (20 %) |
Age-related retirement | 6 | 5 | 11 (55 %) |
Smoking | 3 | 2 | 5 (25 %) |
Drinks of alcohol per week; median (Q1,Q3) | 2.0 (2.0,5.0) | 2.0 (1.0,6.0) | 2.0 (0.0,6.0) |
RA duration (years); median (Q1,Q3) | 10.0 (8,2) | 4.0 (2.0,8.0) | 8.0 (4.0,15.0) |
Medical treatment (biologics) | 6 | 6 | 12 (60 %) |
DAS-28; M(SD) | 3.4 (1.6) | 2.8 (1.0) | 3.1 (1.3) |
CRP; median (Q1,Q3) | 7.0 (5.0,16.0) | 5.0 (5.5,9.0) | 6.5 (5.0,12.5) |
Comorbidity | 8 | 9 | 17 (85 %) |
Daily sitting time Hours/day; M(SD) | 10.7 (1.9) | 9.5 (1.5) | 10.1 (1.8) |
Breaks in sitting time N/day; M(SD) | 50.0 (18.0) | 48.0 (5.0) | 49.0 (13.0) |
Self-reported leisure sitting, Hours/day; M(SD) | 4.0 (1.6) | 5.6 (1.9) | 4.8 (1.9) |
Physical function; median (Q1,Q3)b | 0.6 (0.4,1.0) | 0.6 (0.4,1.1) | 0.6 (0.4–1.1) |
Fatigue; M(SD)c | |||
General fatigue | 11.3 (3.5) | 13.5 (2.7) | 12.4 (3.3) |
Physical fatigue | 11.7 (2.9) | 12.3 (2.7) | 12.0 (2.7) |
Reduced activity | 11.2 (2.8) | 11.5 (2.8) | 11.4 (2.7) |
Reduced motivation | 9.0 (3.8) | 10.6 (3.6) | 9.8 (3.7) |
Mental fatigue | 10.4 (3.5) | 10.5 (2.5) | 10.5 (3.0) |
Pain; median (Q1,Q3)d | 20.5 (6.0,4) | 28.0 (22.0,33.0) | 26.5 (12.0,37.5) |
HR-QoL; M(SD)e | |||
SF-36-PCS | 42.7 (7.6) | 37.1 (6.8) | 39.6 (7.5) |
SF-36-MCS | 50.4 (7.6) | 54.4 (7.6) | 52.6 (7.7) |
Self-efficacy; M(SD)f | 30.2 (3.5) | 29.2 (5.0) | 29.7 (4.2) |
Lipids (mmol/l) | |||
Cholesterol (total); M(SD) | 5.7 (1.2) | 5.2 (1.4) | 5.4 (1.3) |
HDL; M(SD) | 1.5 (0.4) | 1.4 (0.4) | 1.5 (0.4) |
LDL; M(SD) | 3.2 (1.1) | 3.0 (1.1) | 3.2 (1.1) |
Triglyceride; median (Q1,Q3) | 1.7 (1.3,2.2) | 1.0 (0.9,1.8) | 1.4 (0.9,2.1) |
HbA1c (mmol/mol)a; median (Q1,Q3) | 5.6 (5.4,5.8) | 5.6 (5.5,5.7) | 5.6 (5.4,5.8) |
Blood pressure (mmHg); M(SD) | |||
Systolic | 133.8 (18.0) | 122.0 (23.4) | 128.2 (21.0) |
Diastolic | 81.0 (10.2) | 75.0 (10.8) | 78.1 (10.7) |
Weight (kg); M(SD) | 84.3 (22.0) | 72.4 (10.8) | 78.7 (18.2) |
Waist circumference (cm); M(SD) | 88.9 (24.5) | 84.4 (9.3) | 86.8 (18.6) |
BMI; M(SD) | 28.7 (6.5) | 21.9 (4.2) | 25.5 (6.5) |
Waist-hip-ratio; M(SD) | 0.9(0.2) | 0.9 (0.1) | 0.9 (0.1) |